An independent review of the Individual Patient Funding Request (IPFR) process in Wales took place from October to December 2016. The report is now available on the Welsh Government website:
There is also a Written Statement about the review by Vaughan Gething AM, the Cabinet Secretary for Health, Well-being and Sport, which can be found here.
A short summary of the report is as follows:
The review recommends a change to the application of exceptionality whereby if an HTA or other policy is not already in place, the clinician will no longer need to set out how a particular patient is different to others. Instead the report recommends that clinicians demonstrate “significant clinical benefit and reasonable value for money”
A number of recommendations are made around improving consistency, including IPFR panels documenting their decisions clearly; ensuring appropriate expert input in decisions; and establishing an IPFR quality function to provide quality assurance and promote consistency across Wales
NICE and AWMSG:
The review highlights the importance of NICE and AWMSG recommendations in determining cost-effectiveness. It recommends that companies submit to the AWMSG and if a drug is not endorsed, IPFR applications will need to demonstrate clear evidence of clinical benefit for a particular patient to justify the cost
Recommendations are made to improve the communication of IPFR decisions and between patients and clinicians
A review of IPFR paperwork is recommended to reduce the burden on applicants
Subscribers can find more information here.
Non-subscribers can subscribe here